Neurofilament light chain dynamics following ischemic stroke and their modulation by transauricular vagus nerve stimulation.

Sci RepAug 31, 2026 (epub)
Clinical ResearchNeurologyOpen access

Gansheng Tan, Osvaldo J Laurido-Soto, Anna Huguenard et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial examined the dynamics of plasma neurofilament light chain (NfL) in 35 patients after acute ischemic stroke (AIS) and the effects of transauricular vagus nerve stimulation (taVNS). Results indicated that NfL levels increased post-stroke, with higher levels correlating with poorer outcomes. Notably, taVNS was associated with significantly lower NfL levels on Days 3 and 5 compared to sham stimulation.

Key findings

  • NfL levels increased during the acute and early subacute periods after AIS.
  • Higher NfL levels predicted poorer modified Rankin Scale scores at day 90.
  • taVNS was associated with significantly lower NfL levels on Days 3 and 5 compared to sham stimulation.

Why it matters

Understanding the dynamics of NfL as a biomarker for neuroaxonal damage can help clinicians assess long-term recovery in AIS patients. The potential modulation of NfL levels by taVNS may offer insights into new therapeutic strategies to mitigate neuronal injury.

Source

PubMed · PMID 42675092Free full text on PubMed Central

Published in Sci Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.